BXQ-350 is under clinical development by Bexion Pharmaceuticals and currently in Phase II for Malignant Glioma. According to GlobalData, Phase II drugs for Malignant Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BXQ-350 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BXQ-350 overview
BXQ-350 is under development for the treatment of cancers including glioblastoma, lung squamous cell carcinoma, malignant glioma, pancreatic cancer, prostate cancer, ependymoma, pediatric diffuse intrinsic pontine glioma, diffuse midline glioma (DMG) and other solid tumors, Parkinson's disease and unspecified central nervous system disorders. The drug candidate is administered through intravenous injection. The drug candidate is developed based on Dubbed SapC-DOPS technology. BXQ-350 is a nanovesicle formulation of synthetically produced, human lysosomal protein saposin C (sphingolipid activator protein, or SapC, 80 aa) and the phospholipid dioleoylphosphatidylserine (DOPS). BXQ-350 targets phosphatidylserine (PS) lipids.
It was also under development for the treatment of malignant peripheral nerve sheath tumor, head and neck cancer, neuroblastoma, recurrent solid tumors, brain tumor, breast cancer, pineoblasotoma, osteosarcoma, lysosomal storage disorder and unspecified viral infections.
Bexion Pharmaceuticals overview
Bexion Pharmaceuticals (Bexion) is a clinical-stage biopharmaceutical company that develops treatments in oncology and chemotherapy-induced peripheral neuropathy (CIPN). The company’s lead product BXQ-350 which treats cancer, is a novel mechanisms of action impact the tumor and its microenvironment and modulate Ceramide and S1P, bioactive sphingolipids that play a critical role in stemming cancer and pain. It is also pursuing a clinical development plan to address the unmet needs in colorectal cancer and pediatric cancers. Bexion is headquartered in Covington, Kentucky, the US.
For a complete picture of BXQ-350’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
